Zami Aberman
2021
In 2021, Zami Aberman earned a total compensation of $9.8M as Chairman at Pluristem Therapeutics, a 1,856% increase compared to previous year.
Compensation breakdown
| Salary | $556,475 |
|---|---|
| Stock Awards | $8,741,402 |
| Other | $508,074 |
| Total | $9,805,951 |
Aberman received $8.7M in stock awards, accounting for 89% of the total pay in 2021.
Aberman also received $556.5K in salary and $508.1K in other compensation.
Rankings
In 2021, Zami Aberman's compensation ranked 1,068th out of 12,415 executives tracked by ExecPay. In other words, Aberman earned more than 91.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,068 out of 12,415 | 91st |
Division Manufacturing | 363 out of 5,505 | 93rd |
Major group Chemicals And Allied Products | 128 out of 2,375 | 95th |
Industry group Drugs | 108 out of 2,096 | 95th |
Industry Biological Products, Except Diagnostic Substances | 30 out of 449 | 93rd |
Source: SEC filing on February 27, 2023.
Aberman's colleagues
We found two more compensation records of executives who worked with Zami Aberman at Pluristem Therapeutics in 2021.
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019